In Silico Molecular Interaction Studies of Suberoylanilide Hydroxamic Acid and Its Modified Compounds with Histones Deacetylase Class II Homo sapiens as Curative Measure towards Cervical Cancer


The threat of cervical cancer is a serious problem for the women’s health. It is already known that the cause of cervical cancer is definitely HPV (Human Papilloma Virus). The drug development is the most reasonable approach for coping with HPV infection. The development of HDACi (Histone Deacetylase inhibitor) is seen as a feasible method for curing the threat of cervical cancer. Rational drug design is our utilized pipeline for drug development. The LigX MOE-based method has been developed to investigate the molecular interaction of HDAC class IIHomo sapienswith the designed lead compound. The method has found that ligands 1c, 2a, and 2c are indeed feasible to be formulated as drug candidates.

Share and Cite:

Tambunan, U. , Parikesit, A. , Prasetia, T. and Kerami, D. (2013) In Silico Molecular Interaction Studies of Suberoylanilide Hydroxamic Acid and Its Modified Compounds with Histones Deacetylase Class II Homo sapiens as Curative Measure towards Cervical Cancer. Engineering, 5, 203-206. doi: 10.4236/eng.2013.510B043.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] M. H. Schiffman, H. M. Bauer, R. N. Hoover, A. G. Glass, D. M. Cadell, B. B. Rush, D. R. Scott, M. E. Sherman, R. J. Kurman, S. Wacholder, C. K. Stanton and M. M. Manos, “Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial Neoplasia,” Journal of the National Cancer Institute, Vol. 85, No. 12, 1993, pp. 958-964.
[2] WHO, “Cervical Cancer Summary Report,” 2010.
[3] K. E. Palmer, A. B. Jenson, J. C. Kouokam, A. B. Lasnik and S. Ghim, “Recombinant Vaccines for the Prevention of Human Papillomavirus Infection and Cervical Cancer,” Experimental and Molecular Pathology, Vol. 86, No. 3, 2009, pp. 224-233.
[4] J. A. Kahn, “HPV Vaccination for the Prevention of Cervical Intraepithelial Neoplasia,” The New England Journal of Medicine, Vol. 361, No. 3, 2009, pp. 271-278.
[5] D. R. Lowy and J. T. Schiller, “Prophylactic Human Papillomavirus Vaccines,” The Journal of Clinical Investigation, Vol. 116, No. 5, 2006, pp. 1167-1173.
[6] S. Kanodia, D. M. Da Silva and W. M. Kast, “Recent Advances in Strategies for Immunotherapy of Human Papillomavirus-Induced Lesions,” International Journal of Cancer. Journal International du Cancer, Vol. 122, No. 2, 2008, pp. 247-259.
[7] U. S. F. Tambunan, D. Sugiono, T. A. Tochary and A. A. Parikesit, “Computational Study of Post Translation Modification in Chimeric Virus Like Particles Vaccine of Human Papilloma Virus with Virion Capsid L1,” Makara Seri Sains, Vol. 11, 2007.
[8] B. E. Gryder, Q. H. Sodji and A. K. Oyelere, “Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed,” Future Medicinal Chemistry, Vol. 4, No. 4, 2012, pp. 505-524.
[9] T. G. Edwards, K. J. Koeller, U. Slomczynska, K. Fok, M. Helmus, J. K. Bashkin and C. Fisher, “HPV Episome Levels Are Potently Decreased by Pyrrole-Imidazole Polyamides,” Antiviral Research, Vol. 91, No. 2, 2011, pp. 177-186.
[10] M. E. McGee-Lawrence, A. L. McCleary-Wheeler, F. J. Secreto, D. F. Razidlo, M. Zhang, B. A. Stensgard, X. Li, G. S. Stein, J. B. Lian and J. J. Westendorf, “Suberoylanilide Hydroxamic Acid (SAHA; Vorinostat) Causes Bone Loss by Inhibiting Immature Osteoblasts,” Bone, Vol. 48, No. 5, 2011, pp. 1117-1126.
[11] U. S. F. Tambunan and E. K. Wulandari, “Identification of a Better Homo sapiens Class II HDAC Inhibitor through Binding Energy Calculations and Descriptor Analysis,” BMC Bioinformatics, Vol. 11, Suppl. 7, 2010, p. S16.
[12] U. S. F. Tambunan, N. Bramantya and A. A. Parikesit, “In Silico Modification of Suberoylanilide Hydroxamic Acid (SAHA) as Potential Inhibitor for Class II Histone Deacetylase (HDAC),” BMC Bioinformatics, Vol. 12 Suppl. 1, 2011, p. S23.
[13] G. M. Morris, R. Huey and A. J. Olson, “Using Auto-Dock for Ligand-Receptor Docking,” In: A. D. Baxevanis, et al., Eds., Current Protocols in Bioinformatics/Editoral Board, Vol. Chapter 8, Unit 8.14, 2008.
[14] C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, “Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings,” Advanced drug delivery Reviews, Vol. 46, No. 1-3, 2001, pp. 3-26.
[15] W. Kaim and B. Schwederski, “Bioinorganic Chemistry,” Wiley, 1994.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.